Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20019498 | 0.86 | PTPN1 (0.56) | PTPN1NQO2TRPM4ALDH1A1TDP1 | |
| SCHEMBL27858228 | 0.83 | PTPN1 (0.53) | PTPN1NQO2TRPM4ALDH1A1TDP1 | |
| SCHEMBL25800709 | 0.82 | PTPN1 (0.51) | PTPN1NQO2TRPM4CYP1A2LMNA | |
| SCHEMBL7304418 | 0.82 | PTPN1 (0.59) | PTPN1NQO2TRPM4ALDH1A1HPGD | |
| Phenol SCHEMBL11115617 | 0.80 | ALDH1A1 (0.48) | PTPN1NQO2ALDH1A1TDP1HPGD | |
| SCHEMBL722323 | 0.80 | ALDH1A1 (0.57) | PTPN1TRPM4ALDH1A1TDP1HPGD | |
| SCHEMBL7306054 | 0.80 | PTPN1 (0.67) | PTPN1NQO2TRPM4ALDH1A1CYP1A2 | |
| SCHEMBL22747181 | 0.79 | CYP1A2 (0.59) | ALDH1A1HPGDHSD17B10CYP1A2MEN1 | |
| SCHEMBL7955337 | 0.79 | ALDH1A1 (0.42) | PTPN1ALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL16351784 | 0.78 | GPR84 (0.38) | PTPN1NQO2TRPM4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-11739223-B2 | Surface primer compositions and methods of use | ENVISTA (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20170217999-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2017-08-03 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| CN-102348712-A | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | UNIV CARDIFF | 2012-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217999-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | SP1, GPER1, GRIN1 | PTPN1 2427/4885NQO2 2904/4885TRPM4 3661/4885 |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | PTPN1 2649/4885NQO2 1819/4885TRPM4 4394/4885 |
| US-11739223-B2 | Surface primer compositions and methods of use | SP1, GPER1, GRIN1 | PTPN1 2427/4885NQO2 2904/4885TRPM4 3661/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PTPN1 161/4885NQO2 1209/4885TRPM4 2188/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PTPN1 2210/4885NQO2 2074/4885TRPM4 4080/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PTPN1 2210/4885NQO2 2074/4885TRPM4 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.